Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from F.C. Stark and colleagues reveal new findings on cancer vaccines
July 8th, 2009
According to recent research from Ottawa, Canada, "Induction of it functional CD8(+) T-cell response is the important criterion for cancer vaccines, and it. is unclear whether acute or chronic live vectors are better suited for cancer antigen delivery. We have evaluated the tumor protective ability of two recombinant vectors, Listeria monocytogenes (LM) and Salmonella typhimurium (ST), both expressing ovalbumin (OVA)." "Although both vectors induced a similar OVA-specific CD8(+) T-cell response in the long term, LM-OVA induced mainly central-phenotype (T-CM, CD44(high)CD62L(high)), whereas ST-OVA induced mainly effector-phenotype (T-EM, CD44(high)CD62L(low)) cells. Both...
Source: Vaccine Weekly (2009-07-08)
|
